Healthcare Industry News: peripheral artery disease
News Release - November 21, 2016
OrbusNeich Introduces a New Generation COMBO Plus Dual Therapy Stent for Active HealingCOMBO Plus: A combination of traditional drug-eluting stent (DES) components with the addition of a unique biological therapy and enhanced deliverability
HONG KONG, November 21, 2016 -- (Healthcare Sales & Marketing Network) -- OrbusNeich has announced the launch of its latest generation Dual Therapy Stent (DTS), the COMBO Plus. The COMBO Plus has a unique anti-CD34 antibody biological coating that offers an advanced approach to active vessel healing combined with improved deliverability for patients with complex coronary artery disease.
Multiple design features make COMBO Plus a unique and effective option for treating coronary stenosis. Following implantation, the biological coating on the outer surface of the COMBO Plus immediately captures endothelial progenitor cells and initiates the formation of an endothelial layer. This accelerated healing process, leads to earlier return of functionality and may reduce adverse events in the long-term. In concert with the biological layer, a directional coating of bioabsorbable polymer elutes sirolimus to inhibit neointimal hyperplasia.
COMBO Plus employs an enhanced balloon catheter with a lower profile design, lubricious coating and reduced shaft diameters for superior deliverability. The stent design is based on OrbusNeich's R-Stent pattern, which has proven to impart strength and stability during expansion without sacrificing conformability.
"Our design improvements provide superior deliverability and powerful performance for complex daily practice," said David Chien, Chairman of the Board. "COMBO Plus offers physicians a compelling new treatment option for patients with coronary artery disease."
A long-time leader in coronary artery disease treatment, in 2013 OrbusNeich launched the innovative COMBO Dual Therapy Stent, the world's first dual therapy stent to accelerate endothelial coverage and control neointimal proliferation through the combination of the proven Pro-Healing Technology with an abluminal sirolimus drug elution delivered from a bioresorbable polymer that is completely dissipated within 90 days. COMBO is supported by clinical evidence from the REMEDEE family of studies and several other investigator-initiated studies, totaling over 6,000 patients enrolled across more than 26 countries.
About OrbusNeich - Pioneers in life-changing technologies
OrbusNeich is a global pioneer in the provision of life-changing vascular solutions and offers an extensive portfolio of products that set industry benchmarks in vascular intervention. Current products are the world's first dual therapy stent, the COMBO Dual Therapy Stent, stents and balloons marketed under the names of Azule™, Scoreflex™, Sapphire™ II, Sapphire™ II PRO and Sapphire™ II NC, as well as products to treat peripheral artery disease: the Jade™ and Scoreflex™ PTA balloons. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Florida, USA.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to physicians in more than 60 countries. For more information, visit http://www.OrbusNeich.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.